Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
1.610
+0.015 (0.94%)
Nov 11, 2026, 12:12 PM EST - Market open
Black Diamond Therapeutics Employees
Black Diamond Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 3 or 12.50% compared to the previous year. That makes Black Diamond Therapeutics the 38,179th largest employer in the world and 5,456th in the United States.
Employees
21
Change (1Y)
-3
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,098,524
Market Cap
92.52M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -3 | -12.50% |
| Dec 31, 2024 | 24 | -30 | -55.56% |
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunic | 100 |
| Vivani Medical | 42 |
| Milestone Pharmaceuticals | 38 |
| NovaBridge Biosciences | 30 |
| TuHURA Biosciences | 22 |
| Unicycive Therapeutics | 22 |
| Outlook Therapeutics | 17 |
| Kazia Therapeutics | 6 |
BDTX News
- 21 hours ago - Black Diamond Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 1 day ago - Black Diamond Therapeutics’ silevertinib shows efficacy in Phase 2 trial - TheFly
- 1 day ago - Black Diamond Therapeutics price target raised to $14 from $8 at Stifel - TheFly
- 1 day ago - Black Diamond Therapeutics Transcript: Study update - Transcripts
- 1 day ago - Black Diamond Therapeutics Press release: Study update - Filings
- 1 day ago - Black Diamond Therapeutics Slides: Study update - Filings
- 1 day ago - Black Diamond Therapeutics Quarterly report: Q3 2026 - Filings
- 1 day ago - Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update - GlobeNewsWire